San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s highlights in H ...
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...
No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Verywell Health on MSN10d
10 Tips for Living With Early-Stage HER2-Positive Breast CancerHER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...
The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...
Verywell Health on MSN10d
9 Healthy Diet Tips for HER2-Negative Metastatic Breast CancerMedically reviewed by Archana Sharma, DO Eating well can help support your immune system and maintain strength and energy if ...
OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a Notice of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback